or Try an Advanced Search...

    Technical Analysis for NVAX - Novavax, Inc.

    Grade Last Price % Change Price Change
    B 12.90 -4.30% -0.58
    NVAX closed down 4.3 percent on Wednesday, May 15, 2024, on 2.31 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    14 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical NVAX trend table...
    Date Alert Name Type % Chg
    Slingshot Bullish Bullish Swing Setup 0.00%
    Calm After Storm Range Contraction 0.00%
    Parabolic Rise Strength 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Gapped Down Weakness 0.00%
    New 52 Week Closing High Bullish -4.30%
    Older End-of-Day Signals for NVAX ...

       Recent Intraday Alerts

    Alert Time
    5x Volume Pace about 19 hours ago
    Down 10% about 19 hours ago
    Down 1 ATR about 19 hours ago
    2x Volume Pace about 19 hours ago
    1.5x Volume Pace about 19 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    NVAX Chart by TradingView
    Basic chart:

    Profile

    Novavax, Inc. Description

    Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Development Infectious Diseases Vaccines Influenza Coronavirus Vaccination Influenza Vaccine Rabies Seasonal Influenza

    Is NVAX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 15 1 Wall Street Analyst Thinks Novavax Stock Is Going to $10. Is It a Sell?
    May 15 2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
    May 15 Novavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
    May 15 Novavax Stock Just Tripled. Is It Too Late to Buy?
    May 15 Zacks Investment Ideas feature highlights: GameStop, AMC, Novavax, S&P 500 Index ETF and Nvidia
    May 14 Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
    May 14 Zacks Investment Ideas feature highlights: GameStop, AMC, Novavax, Reddit and Tesla
    May 14 Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?
    May 14 Trending tickers: Anglo American, GameStop, Vodafone, Greggs and Novavax
    May 13 Novavax to Participate in BofA Securities 2024 Health Care Conference
    See more NVAX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.0
    52 Week Low 3.5324
    Average Volume 11,536,996
    200-Day Moving Average 5.90
    50-Day Moving Average 5.20
    20-Day Moving Average 5.90
    10-Day Moving Average 7.63
    Average True Range 1.21
    RSI (14) 87.00
    ADX 33.09
    +DI 55.48
    -DI 10.43
    Chandelier Exit (Long, 3 ATRs) 11.36
    Chandelier Exit (Short, 3 ATRs) 7.45
    Upper Bollinger Bands 12.34
    Lower Bollinger Band -0.55
    Percent B (%b) 1.04
    BandWidth 218.51
    MACD Line 1.80
    MACD Signal Line 0.75
    MACD Histogram 1.0493
    Fundamentals Value
    Market Cap 1.53 Billion
    Num Shares 119 Million
    EPS -6.23
    Price-to-Earnings (P/E) Ratio -2.07
    Price-to-Sales 0.46
    Price-to-Book 49.52
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 16.50
    Resistance 3 (R3) 16.37 15.04 15.90
    Resistance 2 (R2) 15.04 14.12 15.11 15.70
    Resistance 1 (R1) 13.97 13.56 13.31 14.10 15.50
    Pivot Point 12.64 12.64 12.31 12.71 12.64
    Support 1 (S1) 11.57 11.72 10.91 11.70 10.30
    Support 2 (S2) 10.24 11.16 10.31 10.10
    Support 3 (S3) 9.17 10.24 9.90
    Support 4 (S4) 9.30